Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 4/20 | 0.54 |
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.44 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA9 | Q16790 | 3/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | GBA1 | P04062 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30980552 | 0.85 | LGALS3 (0.54) | LGALS3ADAMTS5ADAMTS4CA1CA2 | |
| SCHEMBL30980721 | 0.85 | LGALS3 (0.49) | LGALS3ADAMTS5ADAMTS4CA1CA2 | |
| SCHEMBL24916691 | 0.81 | CA1 (0.47) | LGALS3ADAMTS5ADAMTS4CA1CA2 | |
| SCHEMBL25343142 | 0.79 | LGALS3 (0.51) | LGALS3ADAMTS5ADAMTS4CA1CA2 | |
| SCHEMBL16926319 | 0.79 | LGALS3 (0.67) | LGALS3ADAMTS5ADAMTS4CA1CA2 | |
| SCHEMBL20841752 | 0.77 | LGALS3 (0.65) | LGALS3ADAMTS5ADAMTS4MAPK1 | |
| SCHEMBL29339924 | 0.77 | LGALS3 (0.64) | LGALS3ADAMTS5ADAMTS4CA1CA2 | |
| SCHEMBL30180631 | 0.76 | LGALS3 (0.46) | LGALS3ADAMTS5ADAMTS4CA1CA2 | |
| SCHEMBL25976612 | 0.76 | CA1 (0.45) | LGALS3CA1CA2CA9CA12 | |
| SCHEMBL25974170 | 0.76 | CA1 (0.45) | LGALS3CA1CA2CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4651902-A2 | ASGPR BINDING COMPOUNDS AND CONJUGATES | Lycia Therapeutics, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-4651901-A1 | CYCLING LYSOSOMAL TARGETING ANTIBODY CONJUGATES | Lycia Therapeutics, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| WO-2025035040-A1 | LYSOSOMAL TARGETING BIFUNCTIONAL MOLECULES FOR DEGRADATION OF MUSCLE-SPECIFIC KINASE AUTOANTIBODIES | LYCIA THERAPEUTICS, INC. (US) | 2025-02-13 | — | — | WO | disclosed |
| WO-2024155747-A2 | ASGPR BINDING COMPOUNDS AND CONJUGATES | LYCIA THERAPEUTICS, INC. (US) | 2024-07-25 | — | — | WO | disclosed |